Hims & Hers Health opened a waitlist for its $149 cash‑pay Wegovy® and Ozempic® products on March 18 2026, following a partnership with Novo Nordisk that gives the telehealth company immediate access to the two most popular GLP‑1 weight‑loss drugs in the United States.
The partnership allows Hims & Hers to offer FDA‑approved branded medications alongside its own compounded formulations, a shift that reduces legal risk and enhances brand credibility. The $149 price point is a starting cash‑pay rate designed to attract price‑sensitive consumers who might otherwise seek cheaper, compounded options.
The U.S. obesity‑drug market is projected to reach roughly $80 billion by 2035, while the global GLP‑1 market is expected to hit $216 billion in the same year, underscoring the substantial revenue potential of the partnership.
Hims & Hers reported 28 % year‑over‑year revenue growth to $617.8 million in Q4 2025 and 59 % growth to $2.35 billion for the full year. Gross margin fell to 72 % in Q4 2025 from 77 % in Q4 2024, and the full‑year margin dropped to 74 % from 79 % in 2024, reflecting the company’s shift toward branded GLP‑1s. Management guided Q1 2026 revenue to $600 million–$625 million, below analyst expectations, and full‑year 2026 revenue to $2.7 billion–$2.9 billion, indicating a sequential ramp in growth.
CEO Andrew Dudum said the partnership would create a new model for everyday people, while CFO Yemi Okupe highlighted the platform’s scalability and the revenue growth achieved in 2025. Analysts have mixed views, with some upgrading price targets after the deal, but others remain cautious due to slower revenue growth and regulatory risks.
The announcement was well received by investors, reflecting confidence in the partnership’s ability to reduce legal exposure and tap a rapidly expanding market. The shift to branded drugs is expected to strengthen Hims & Hers’ competitive position in the telehealth and consumer health space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.